Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Eribulin

4 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCBRE1599

    04/11/2016

    A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

    Treatment

    VICCBRE1462

    03/08/2016

    A Phase I Dose Escalation Study of POL6326 with Eribulin in Patients with Relapsed Metastatic Breast Cancer

    Treatment

    VICCBRE1246

    03/13/2015

    Enhancing Efficacy of Chemotherapy in Triple-Negative/Basal-Like Breast Cancers by Targeting Macrophages: A Phase Ib/II Study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

    Treatment

    VICCBRE1391

    04/24/2014

    A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients


    Print this page for your doctor